Computational and experimental studies on the interaction between butyrylcholinesterase and fluoxetine: implications in health and disease

Abstract

1. Butyrylcholinesterase (BChE) is a serine esterase that plays a role in the detoxification of natural as well as synthetic ester-bond-containing compounds. Alterations in BChE activity are associated with a number of diseases. Cholinergic system abnormalities in particular are correlated with the formation of senile plaques in Alzheimer’s disease (AD), and administration of cholinesterase inhibitors is a common therapeutic approach used to treat AD.

2. Here, our aim was to study the interaction between BChE and fluoxetine.

3. Molecular docking simulations revealed that fluoxetine penetrated deep into the active-site gorge of BChE and that it was engaged in stabilizing noncovalent interactions with multiple subsites. In substrate kinetic studies, the V_m, K_m, k_cat and k_cat/K_m values were found to be 20.59 ± 0.36 U mg⁻¹ protein, 194 ± 14 µM, 1.3 × 10⁸ s⁻¹ and 6.7 × 10⁵ µM⁻¹s⁻¹, respectively. Based on inhibitory studies, fluoxetine appeared to inhibit BChE competitively, with an IC₅₀ value of 104 µM and a K_i value of 36.3 ± 4.7 µM.

4. Overall, both the low K_i value and the high number of BChE–fluoxetine interactions suggest that fluoxetine is a potent inhibitor of BChE, although in vivo mechanisms for the direct effects of BChE inhibition on various pathologies remain to be further investigated.

Keywords:

• Fluoxetine
• butyrylcholinesterase
• molecular docking
• enzyme inhibition

Disclosure statement

No potential conflict of interest was reported by the authors.